Press release
Cytomegalovirus Infection Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech
"Cytomegalovirus Infection Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus Infection Market.
The Cytomegalovirus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cytomegalovirus Infection Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Cytomegalovirus Infection treatment therapies with a considerable amount of success over the years.
*
Cytomegalovirus Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus Infection treatment
*
Emerging Cytomegalovirus Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus Infection market in the coming years.
*
In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Helocyte, Inc., announced that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial. The study aims to assess the effectiveness of Triplex, a cytomegalovirus (CMV) vaccine, when given to human leukocyte antigen (HLA)-matched related stem cell donors to reduce CMV occurrences in patients undergoing hematopoietic stem cell transplantation (HSCT).
*
In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrated superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
Cytomegalovirus Infection Overview
Cytomegalovirus Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.
Get a Free Sample PDF Report to know more about Cytomegalovirus Infection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Cytomegalovirus Infection Drugs Under Different Phases of Clinical Development Include:
*
Research programme: antiviral therapeutics TSRL
*
SYN002: Synklino
*
Posoleucel: AlloVir
*
mRNA-1647: Moderna
*
CMV TCR T cell therapy: China Immunotech
*
NPC-21: Nobelpharma
*
HB-101: Hookipa Biotech GmbH
*
Cytomegalovirus immune globulin: Biotest
*
Posoleucel: AlloVir
*
VBI-1501A: VBI Vaccines
*
LTV 20: Lion TCR
*
Maribavir: Shire
*
V160: Merck Sharp & Dohme
*
Maribavir: Takeda
*
Valganciclovir: CSL Behring
*
Brincidofovir: Chimerix
*
Everolimus: Novartis
*
HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus Infection Route of Administration
Cytomegalovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intranasal
*
Intrathecal
*
Intravenous
*
Oral
*
Oral/Intravenous
*
Parenteral
*
Subcutaneous
*
Subcutaneous/Intramuscular
*
Transdermal
Cytomegalovirus Infection Molecule Type
Cytomegalovirus Infection Products have been categorized under various Molecule types, such as
*
Antisense oligonucleotide
*
Gene therapy
*
Hormones
*
Neuropeptides
*
Oligonucleotides
*
Small Molecule
*
Triglyceride
Cytomegalovirus Infection Pipeline Therapeutics Assessment
*
Cytomegalovirus Infection Assessment by Product Type
*
Cytomegalovirus Infection By Stage and Product Type
*
Cytomegalovirus Infection Assessment by Route of Administration
*
Cytomegalovirus Infection By Stage and Route of Administration
*
Cytomegalovirus Infection Assessment by Molecule Type
*
Cytomegalovirus Infection by Stage and Molecule Type
DelveInsight's Cytomegalovirus Infection Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Cytomegalovirus Infection product details are provided in the report. Download the Cytomegalovirus Infection pipeline report to learn more about the emerging Cytomegalovirus Infection therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Cytomegalovirus Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus Infection are - Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others .
Cytomegalovirus Infection Pipeline Analysis:
The Cytomegalovirus Infection pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
*
Cytomegalovirus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus Infection drugs and therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Cytomegalovirus Infection Pipeline Market Drivers
*
Increasing Prevalence of Cytomegalovirus Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus Infection Market.
Cytomegalovirus Infection Pipeline Market Barriers
*
However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus Infection Market growth.
Scope of Cytomegalovirus Infection Pipeline Drug Insight
*
Coverage: Global
*
Key Cytomegalovirus Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
*
Key Cytomegalovirus Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
*
Cytomegalovirus Infection Therapeutic Assessment: Cytomegalovirus Infection current marketed and Cytomegalovirus Infection emerging therapies
*
Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection market drivers and Cytomegalovirus Infection market barriers
Request for Sample PDF Report for Cytomegalovirus Infection Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Cytomegalovirus Infection Report Introduction
2. Cytomegalovirus Infection Executive Summary
3. Cytomegalovirus Infection Overview
4. Cytomegalovirus Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus Infection Pipeline Therapeutics
6. Cytomegalovirus Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus Infection Mid Stage Products (Phase II)
8. Cytomegalovirus Infection Early Stage Products (Phase I)
9. Cytomegalovirus Infection Preclinical Stage Products
10. Cytomegalovirus Infection Therapeutics Assessment
11. Cytomegalovirus Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus Infection Key Companies
14. Cytomegalovirus Infection Key Products
15. Cytomegalovirus Infection Unmet Needs
16 . Cytomegalovirus Infection Market Drivers and Barriers
17. Cytomegalovirus Infection Future Perspectives and Conclusion
18. Cytomegalovirus Infection Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-infection-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-merck-sharp-dohme-llc-chimerix-vbi-vaccines-atara-biotherapeutics-spybiotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus Infection Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech here
News-ID: 3947610 • Views: …
More Releases from ABNewswire
Quest Auto Sales Transforms Used Cars for Sale Market with a Customer-First Fina …
Quest Auto Sales at 4501 L St, Omaha, offers flexible financing and transparent pricing on pre-owned vehicles, driving growth through customer referrals and personalized service in the local market.
The pre-owned vehicle market in Omaha is shifting as Quest Auto Sales [https://www.questautosales.com/] introduces a financing approach that prioritizes customer needs over rigid sales quotas. Located at 4501 L St in Omaha, NE 68117, the dealership has built its reputation on flexible…
Crown Reconstruction Services Inc. Introduces Transparent Pricing Model for Roof …
Crown Reconstruction Services Inc. in Laguna Beach introduces itemized pricing for roofing projects, giving property owners detailed cost breakdowns before work begins.
A Laguna Beach-based contractor is addressing one of the construction industry's most persistent challenges: pricing transparency. Crown Reconstruction Services Inc. [https://crownreconstructionservices.com/], operating from its office at 2055 Laguna Canyon Rd, has implemented a new pricing structure that provides homeowners with detailed, itemized estimates before any work begins.
The roofing industry…
Blue Ocean Life Brings Ocean-Inspired Calm, Resilience, and Freedom to Everyday …
Blue Ocean Life Company LLC spreads a message of healing, balance, and coastal calm through its mission-driven apparel and lifestyle brand. With designs like "Saltwater Heals Everything" and "Find Your Calm," the Cape Cod-based company blends style with purpose, reminding people of the restorative power of the ocean while addressing rising mental health challenges through lifestyle design.
CAPE COD, Mass. - Blue Ocean Life Company LLC is spreading a message of…
Third Hemisphere Strengthens Position as Leading Investment Communications Speci …
Jeremy Liddle [https://thirdhemisphere.agency/about-us] Third Hemisphere has established itself as a specialist in alternative investment communications, expanding capabilities across private credit, growth equity, and venture capital. The agency's regional positioning reflects the increasing sophistication of the Asia-Pacific investment landscape, where institutional allocators are diversifying beyond traditional public markets into private and alternative asset strategies.
The alternative investment environment in the region demands communications expertise that integrates financial understanding, Third Hemisphere, a full…
More Releases for Cytomegalovirus
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Cytomegalovirus Solutions Soar: Cytomegalovirus Treatment Market Targets US$ 326 …
The Cytomegalovirus (CMV) Treatment Market stands at the forefront of addressing a formidable viral adversary that often operates under the radar. Cytomegalovirus, a member of the herpesvirus family, can pose serious threats to individuals with weakened immune systems, such as transplant recipients and those living with HIV. As a result, the development of effective treatments has become a critical endeavor in the realm of infectious diseases.
In 2022, the global cytomegalovirus…
Cytomegalovirus Treatment Market Will Generate Record Revenue by 2029
The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%-56.0% in SOT recipients and 30.0%-70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in…
Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28
The global cytomegalovirus diagnostics market size was valued at USD 73.6 million in 2021, growing at a CAGR of 6.1% during the forecast period 2022-28. A common herpesvirus called cytomegalovirus can produce a wide range of symptoms, from little to no symptoms to fever and tiredness to severe symptoms affecting the brain, eyes, and other internal organs. Plasma, sperm, saliva, urinalysis, and breast milk can all be used as…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
